- Home
- MQY vs JANX Comparison
MQY vs JANX Comparison
Compare MQY & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MQY | JANX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 836.1M | 790.3M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MQY | JANX |
|---|---|---|
| Price | $11.59 | $14.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $53.60 |
| AVG Volume (30 Days) | 311.0K | ★ 818.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $209.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.52 | $12.12 |
| 52 Week High | $11.97 | $35.34 |
Technical Indicators
Market Signals| Indicator | MQY | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 52.69 |
| Support Level | $11.49 | $13.80 |
| Resistance Level | $11.78 | $15.49 |
| Average True Range (ATR) | 0.10 | 0.51 |
| MACD | -0.03 | 0.12 |
| Stochastic Oscillator | 12.66 | 66.89 |
Price Performance
Historical ComparisonAbout MQY Blackrock MuniYield Quality Fund Inc.
Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.